Evidence map›Paper›PMID 30926675›Full record

ArticleThe oncologist2019

The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma.

Umang Swami, Petros Grivas, Neeraj Agarwal

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Umang SwamiDepartment of Hematology, Oncology and Blood and Marrow Transplantation, The Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.ORCID 0000-0003-3518-0411
Petros GrivasDivision of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-3965-3394
Neeraj AgarwalDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA neeraj.agarwal@hci.utah.edu.ORCID 0000-0003-1076-0428

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary reviews current progress in neoadjuvant immunotherapy for muscle‐invasive localized urothelial carcinoma, highlighting opportunities and challenges with recent neoadjuvant immunotherapy trials.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsCisplatinHumansNeoadjuvant TherapyCisplatin

Identifiers

PMID30926675
PMCPMC6516125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.